Lecanemab's Promise and Peril: Alzheimer's Treatment Dilemma

of monoclonal amyloid beta therapy, including likelihood of side effects and overall burden on the patient, according to researchers at the 2024 annual meeting of the may help some patients by lowering the level of beta-amyloid protein in the brain.

Lecanemab is cost-prohibitive for many patients, with an annual price tag of $26,000. Treatment also requires monthly infusions, a PET, intravenous administration, lab work, multiple MRIs, and potentially an Medicare covers the majority of services, but patients are responsible for deductibles and copays, an estimated $7000 annually, according to Shari Ling, MD, deputy chief medical officer with the US Centers for Medicare & Medicaid Services, who also spoke during the session. Supplemental or other insurance such as Medicaid are also not included in this estimate.

The Medicare population is growing more complex over time, Ling said. In 2021, 54% of beneficiaries had five or more comorbidities, which can affect eligibility for lecanemab. "Across the healthcare system, we are learning what is necessary for coordination of delivery, for evaluation of people who receive these treatments, and for the care that is not anticipated," Ling noted.All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC. This website also contains material copyrighted by 3rd parties.

Alzheimer Disease Antidementia Agents Mild Cognitive Impairment MCI - Mild Cognitive Impairment Minimal Cognitive Impairment MCI Mild Cognitive Impairment (MCI) Cognitive Impairment Biomarker Biological Marker Multi-Biomarker Disease Activity MBDA Multibiomarker Disease Activity Brain Impairment Medicare Amyloid Beta CSF Cerebrospinal Fluid Medicaid Geriatrics

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Promise Project Plans ‘Beautiful Promise’ Spring Fundraiser for May 7Proceeds from the event 'Beautiful Promise' benefit children with learning disabilities.
Source: wwd - 🏆 24. / 68 Read more »

Lecanemab Extension Study for AD Offers Mixed ResultsThe lecanemab open-label extension trial for AD showed no new safety signals, but the placebo roll-over group failed to show the gains seen in the experimental arm.
Source: Medscape - 🏆 386. / 55 Read more »

Alzheimer’s is 7th-leading cause of death in Ohio, says recent reportThe Alzheimer’s Association report examined the impact of Alzheimer’s and dementia, Alzheimer’s-related deaths, caregiving and dementia care workforce shortages.
Source: clevelanddotcom - 🏆 301. / 63 Read more »

The cost to reunite: Refugee program gives new hope to families with relatives in perilThe State Department usually works with nonprofit groups that specialize in refugee issues to help people as they first arrive in the U.S. Through Welcome...
Source: dallasnews - 🏆 18. / 71 Read more »

'I was afraid for my life' — Orlando Bloom puts himself in peril for new TV seriesOrlando Bloom wanted to test himself for his latest adventure project.
Source: wjxt4 - 🏆 246. / 63 Read more »

'I was afraid for my life' — Orlando Bloom puts himself in peril for new TV seriesOrlando Bloom wanted to test himself for his latest adventure project.
Source: KPRC2 - 🏆 80. / 68 Read more »